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Purpose of the study
To evaluate the use of enfuvirtide-based HAART regimens
in patients receiving chemotherapy for lymphoma, where
the concomitant use of antineoplastic agents with PI- or
NNRTI-based regimens is difficult due to P450 enzyme
and p-glycoprotein induction and inhibition.
Methods
This was a retrospective analysis of five HIV patients
treated with an enfuvirtide-based HAART regimen while
receiving chemotherapy for lymphoma. Data were gath-
ered from their case notes and information regarding
potential drug interactions was obtained from the HIV
specialist pharmacist and literature review.
Summary of results
The five patients studied were all male, median age of 30
yrs (range 28–42), with no significant co-morbidities.
Median baseline HIV viral load (VL) was 90,000 copies/
ml (range 11,759–3,035,664). Patients 1 and 2 with
Burkitts Lymphoma, and Patient 3 with HIV-assoc DLBCL
of anus (stage 1E) were treated with CODOX-M/IVAC;
Patient 4 had high grade B cell lymphoma and received r-
CHOP. Each of these patients were treated with tenofovir/
emtricitabine and enfuvirtide. Patient 5 had plasmablastic
high grade B cell NHL of the pancreas, which recurred in
the leg. He received ESHAP/Ifosphamide/Cytarabine and
his HAART regimen was zidovudine/lamivudine/tenofo-
vir with enfuvirtide. Initial virological response was excel-
lent in four patients, with all having more than 2 log drop
in VL within the first 3–7 weeks of treatment. VL was
undetectable within 12 weeks in Patients 1 and 2. Patient
4 initially did very well, followed by virological relapse.
He subsequently admitted to poor compliance and resist-
ance testing revealed lamivudine resistance. Patient 5 had
an initial excellent virological response but the lymphoma
progressed despite therapy and he died 8 weeks into treat-
ment. Patient 3 had a 0.9 log drop in VL at week 5 and
undetectable VL at week 19 which was then sustained
throughout treatment. Two patients developed severe
mucositis due to methotrexate, but none of the patients
required dose reductions in their chemotherapy regimens.
Two patients developed injection site reactions with enfu-
virtide but continued to tolerate it for the duration of the
chemotherapy. No patients developed renal dysfunction.
Conclusion
An enfuvirtide-based HAART regimen is efficacious and
useful in HIV patients undergoing chemotherapy for lym-
phoma due to its lack of drug interactions with the antin-
eoplastic agents.
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